Breaking News Instant updates and real-time market news.

HOOD

Robinhood

$70.50 /

+23.8 (+50.96%)

07:05
08/05/21
08/05
07:05
08/05/21
07:05

Robinhood down 11% after filing to sell up to 97.88M shares for shareholders

Robinhood shares are down $7.81, or 11%, to $62.58 in pre-market trading following the company having filed with the SEC a prospectus related to the offer and sale from time to time of up to 97,876,033 shares of Class A common stock of Robinhood Markets, Inc. by certain selling stockholders.

  • 29

    Jul

HOOD Robinhood
$70.50 /

+23.8 (+50.96%)

07/29/21
Fly Intel: Top five analyst initiations
07/29/21 Atlantic Equities
Robinhood initiated with an Overweight at Atlantic Equities

TODAY'S FREE FLY STORIES

Periodicals
U.S. trade official called India's MasterCard ban 'draconian,' Reuters reports » 15:39
09/19/21
09/19
15:39
09/19/21
15:39
MA

MasterCard

$343.00 /

-3.325 (-0.96%)

, AXP

American Express

$163.98 /

+1.345 (+0.83%)

A senior U.S. trade…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MA MasterCard
$343.00 /

-3.325 (-0.96%)

AXP American Express
$163.98 /

+1.345 (+0.83%)

MA MasterCard
$343.00 /

-3.325 (-0.96%)

09/03/21 Deutsche Bank
Deutsche says many concerns over Visa and MasterCard are minor
08/17/21 JPMorgan
MasterCard price target raised to $430 from $427 at JPMorgan
08/12/21 Daiwa
MasterCard downgraded to Neutral from Outperform at Daiwa
08/02/21 Mizuho
MasterCard price target raised to $450 from $435 at Mizuho
AXP American Express
$163.98 /

+1.345 (+0.83%)

09/16/21
Fly Intel: Top five analyst upgrades
09/16/21 BofA
American Express upgraded to Neutral at BofA on accelerating QTD billings
09/16/21 BofA
American Express upgraded to Neutral from Underperform at BofA
08/30/21
Fly Intel: Top five analyst initiations
MA MasterCard
$343.00 /

-3.325 (-0.96%)

AXP American Express
$163.98 /

+1.345 (+0.83%)

MA MasterCard
$343.00 /

-3.325 (-0.96%)

AXP American Express
$163.98 /

+1.345 (+0.83%)

MA MasterCard
$343.00 /

-3.325 (-0.96%)

AXP American Express
$163.98 /

+1.345 (+0.83%)

MA MasterCard
$343.00 /

-3.325 (-0.96%)

AXP American Express
$163.98 /

+1.345 (+0.83%)

Periodicals
Fauci says key data on J&J, Moderna COVID boosters weeks away, Reuters reports » 15:31
09/19/21
09/19
15:31
09/19/21
15:31
JNJ

Johnson & Johnson

$164.77 /

-0.41 (-0.25%)

, MRNA

Moderna

$429.30 /

-11.54 (-2.62%)

President Joe…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$164.77 /

-0.41 (-0.25%)

MRNA Moderna
$429.30 /

-11.54 (-2.62%)

JNJ Johnson & Johnson
$164.77 /

-0.41 (-0.25%)

09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades J&J to Equal Weight amid limited mid-term newsflow
MRNA Moderna
$429.30 /

-11.54 (-2.62%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
08/12/21 Wells Fargo
Wells says Moderna vaccine looks more effective than Pfizer's against Delta
08/06/21
Fly Intel: Top five analyst downgrades
JNJ Johnson & Johnson
$164.77 /

-0.41 (-0.25%)

MRNA Moderna
$429.30 /

-11.54 (-2.62%)

JNJ Johnson & Johnson
$164.77 /

-0.41 (-0.25%)

MRNA Moderna
$429.30 /

-11.54 (-2.62%)

JNJ Johnson & Johnson
$164.77 /

-0.41 (-0.25%)

MRNA Moderna
$429.30 /

-11.54 (-2.62%)

JNJ Johnson & Johnson
$164.77 /

-0.41 (-0.25%)

MRNA Moderna
$429.30 /

-11.54 (-2.62%)

Hot Stocks
Seagen, Genmab present interim results from innovaTV 205 study » 15:11
09/19/21
09/19
15:11
09/19/21
15:11
SGEN

Seagen

$156.26 /

+2.57 (+1.67%)

, GMAB

Genmab

$43.10 /

+0.845 (+2.00%)

Seagen (SGEN) and Genmab…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SGEN Seagen
$156.26 /

+2.57 (+1.67%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

SGEN Seagen
$156.26 /

+2.57 (+1.67%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
GMAB Genmab
$43.10 /

+0.845 (+2.00%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
SGEN Seagen
$156.26 /

+2.57 (+1.67%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

Hot Stocks
Verastem highlights data from investigator-sponsored Phase 1/2 FRAME study » 15:08
09/19/21
09/19
15:08
09/19/21
15:08
VSTM

Verastem

$2.76 /

+0.06 (+2.23%)

Verastem Oncology…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VSTM Verastem
$2.76 /

+0.06 (+2.23%)

VSTM Verastem
$2.76 /

+0.06 (+2.23%)

07/01/21 Alliance Global Partners
Verastem initiated with a Buy at Alliance Global Partners
05/24/21 BTIG
Verastem upgraded to Buy from Neutral at BTIG
05/24/21 BTIG
Verastem upgraded to Buy from Neutral at BTIG
VSTM Verastem
$2.76 /

+0.06 (+2.23%)

VSTM Verastem
$2.76 /

+0.06 (+2.23%)

Hot Stocks
Mirati Therapeutics announces results from cohort of Phase 1/2 KRYSTAL-1 study » 15:04
09/19/21
09/19
15:04
09/19/21
15:04
MRTX

Mirati Therapeutics

$173.76 /

+4.65 (+2.75%)

Mirati Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$173.76 /

+4.65 (+2.75%)

MRTX Mirati Therapeutics
$173.76 /

+4.65 (+2.75%)

09/07/21 JPMorgan
Mirati Therapeutics price target lowered to $203 from $205 at JPMorgan
08/26/21 Morgan Stanley
Mirati Therapeutics initiated with an Equal Weight at Morgan Stanley
08/26/21 Morgan Stanley
Mirati Therapeutics initiated with an Equal Weight at Morgan Stanley
06/04/21 Citi
Mirati Therapeutics upgraded to Buy from Neutral at Citi
MRTX Mirati Therapeutics
$173.76 /

+4.65 (+2.75%)

  • 28
    Oct
MRTX Mirati Therapeutics
$173.76 /

+4.65 (+2.75%)

Hot Stocks
Merck presents first results from Phase 3 KEYNOTE-716 trial » 14:57
09/19/21
09/19
14:57
09/19/21
14:57
MRK

Merck

$71.70 /

-0.25 (-0.35%)

Merck announced the first…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades Merck to Equal Weight, awaits strategic action
09/07/21 Morgan Stanley
Merck downgraded to Equal Weight from Overweight at Morgan Stanley
MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

Hot Stocks
Merck presents full results from pivotal Phase 3 KEYNOTE-826 trial » 14:54
09/19/21
09/19
14:54
09/19/21
14:54
MRK

Merck

$71.70 /

-0.25 (-0.35%)

Merck announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades Merck to Equal Weight, awaits strategic action
09/07/21 Morgan Stanley
Merck downgraded to Equal Weight from Overweight at Morgan Stanley
MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

Hot Stocks
Spectrum presents results from Cohort 4 of ZENITH20 clinical trial » 14:46
09/19/21
09/19
14:46
09/19/21
14:46
SPPI

Spectrum

$2.44 /

+0.1 (+4.27%)

Spectrum Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SPPI Spectrum
$2.44 /

+0.1 (+4.27%)

SPPI Spectrum
$2.44 /

+0.1 (+4.27%)

08/18/21 B. Riley
Spectrum price target lowered to $6 from $8 at B. Riley
06/01/21 H.C. Wainwright
H.C. Wainwright remains bullish on Spectrum as FDA inspects Rolontis facility
10/26/20 H.C. Wainwright
Spectrum won't need to refile as CRL not given, says H.C. Wainwright
SPPI Spectrum
$2.44 /

+0.1 (+4.27%)

SPPI Spectrum
$2.44 /

+0.1 (+4.27%)

Hot Stocks
Exelixis announces detailed Phase 1b results from cohort 6 of COSMIC-021 trial » 14:42
09/19/21
09/19
14:42
09/19/21
14:42
EXEL

Exelixis

$20.74 /

+0.205 (+1.00%)

Exelixis announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

Hot Stocks
AstraZeneca presents data from Phase II DESTINY-Lung01 trial of ENHERTU » 14:39
09/19/21
09/19
14:39
09/19/21
14:39
AZN

AstraZeneca

$55.56 /

-1.04 (-1.84%)

Detailed primary results…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
09/17/21 Morgan Stanley
AstraZeneca price target raised to 10,000 GBp from 9,800 GBp at Morgan Stanley
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

Hot Stocks
Novartis announces results of final OS analysis of Phase III MONALEESA-2 study » 09:41
09/19/21
09/19
09:41
09/19/21
09:41
NVS

Novartis

$83.49 /

-0.88 (-1.04%)

Novartis has announced…

Novartis has announced results of the final overall survival analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali in combination with letrozole compared to placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with no prior systemic treatment for advanced disease. Kisqali in combination with letrozole met its key secondary endpoint of OS, demonstrating a statistically significant and clinically meaningful improvement in survival. The analysis found that after a median follow-up of over six and a half years, the longest for any CDK4/6 inhibitor trial to date, the improvement in the median OS was over one year. MONALEESA-2 showed that after five years, patients treated with Kisqali in combination with letrozole had more than a 50% chance of survival. In MONALEESA-2, a 12-month delay in time to chemotherapy was observed with Kisqali compared to those taking letrozole alone. With this longer follow-up, no new safety signals were observed; adverse events were consistent with previously reported Phase III trial results for Kisqali. In MONALEESA-2, the primary endpoint progression-free survival was met at the initial analysis. These new OS results mark the third statistically significant and clinically meaningful survival benefit achieved by Kisqali in the MONALEESA program. Novartis will submit the data to global health authorities to support label updates.

ShowHide Related Items >><<
NVS Novartis
$83.49 /

-0.88 (-1.04%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
NVS Novartis
$83.49 /

-0.88 (-1.04%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

Hot Stocks
AstraZeneca presents results from head-to-head DESTINY-Breast03 Phase III trial » 08:43
09/19/21
09/19
08:43
09/19/21
08:43
AZN

AstraZeneca

$55.56 /

-1.04 (-1.84%)

Detailed positive results…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
09/17/21 Morgan Stanley
AstraZeneca price target raised to 10,000 GBp from 9,800 GBp at Morgan Stanley
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

Hot Stocks
AstraZeneca presents updated results from CASPIAN Phase III trial » 08:37
09/19/21
09/19
08:37
09/19/21
08:37
AZN

AstraZeneca

$55.56 /

-1.04 (-1.84%)

IUpdated results from the…

IUpdated results from the CASPIAN Phase III trial showed AstraZeneca's Imfinzi, or durvalumab, in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival benefit at three years for adults with extensive-stage small cell lung cancer treated in the 1st-line setting. These data, which show the longest survival update ever reported for an immunotherapy treatment in this setting, were presented during a mini-oral session on 18 September 2021 at the European Society of Medical Oncology Congress 2021. The CASPIAN trial met the primary endpoint of OS in June 2019, reducing the risk of death by 27%, which has formed the basis of regulatory approvals in many countries around the world. Updated results were previously presented during the ASCO20 Virtual Scientific Program in May 2020 with a median follow up of more than two years. The latest results for Imfinzi plus chemotherapy showed sustained efficacy after a median follow up of more than three years for censored patients, with a 29% reduction in the risk of death versus chemotherapy alone. Updated median OS was 12.9 months versus 10.5 for chemotherapy. The results included a planned exploratory analysis, where an estimated 17.6% of patients treated with Imfinzi plus chemotherapy were alive at three years, versus 5.8% of patients treated with chemotherapy alone. The survival benefits were consistent across all subgroups, in line with previous analyses. Imfinzi plus chemotherapy continued to demonstrate a well-tolerated safety profile consistent with the known profiles of these medicines. Results showed 32.5% of patients experienced a serious adverse event with Imfinzi plus chemotherapy versus 36.5% with chemotherapy alone. Imfinzi in combination with etoposide and either carboplatin or cisplatin is approved in the 1st-line setting of ES-SCLC in more than 55 countries, including the US, Japan, China and across the EU. Imfinzi is also being tested following concurrent chemoradiation therapy in patients with limited-stage SCLC in the ADRIATIC Phase III trial as part of a broad development program. In addition, Imfinzi is also approved to treat non-small cell lung cancer in the curative-intent setting of unresectable, Stage III disease after CRT in the US, Japan, China, across the EU and in many other countries, based on results from the PACIFIC Phase III trial.

ShowHide Related Items >><<
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
09/17/21 Morgan Stanley
AstraZeneca price target raised to 10,000 GBp from 9,800 GBp at Morgan Stanley
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

On The Fly
On the Fly: The Week in SPAC News » 08:30
09/19/21
09/19
08:30
09/19/21
08:30
PPGH

Poema Global

$9.87 /

+0.02 (+0.20%)

, GGR

Gogoro

/

+

, ARTAU

Artisan Acquisition

$10.10 /

+ (+0.00%)

, MOTV

Motive Capital

$9.87 /

+ (+0.00%)

, KVSB

Khosla Ventures Acquisition Co. II

$10.28 /

+0.225 (+2.24%)

, KIND

Nextdoor

/

+

, FLYA

Soar Technology Acquisition

/

+

, EDNC

Endurance Acquisition

/

+

, CIIG

CIIG Capital Partners II

/

+

, AEHA

Aesther Healthcare Acquisition

/

+

, WINV

Winvest Acquisition

/

+

, SIER

Sierra Lake Acquisition

/

+

, PAFO

Pacifico Acquisition

/

+

In SPAC news this week,…

ShowHide Related Items >><<
PPGH Poema Global
$9.87 /

+0.02 (+0.20%)

MOTV Motive Capital
$9.87 /

+ (+0.00%)

KVSB Khosla Ventures Acquisition Co. II
$10.28 /

+0.225 (+2.24%)

ARTAU Artisan Acquisition
$10.10 /

+ (+0.00%)

KVSB Khosla Ventures Acquisition Co. II
$10.28 /

+0.225 (+2.24%)

KVSB Khosla Ventures Acquisition Co. II
$10.28 /

+0.225 (+2.24%)

ARTAU Artisan Acquisition
$10.10 /

+ (+0.00%)

KVSB Khosla Ventures Acquisition Co. II
$10.28 /

+0.225 (+2.24%)

Conference/Events
Truist to hold a virtual bus tour » 04:55
09/19/21
09/19
04:55
09/19/21
04:55
ATVI

Activision Blizzard

$79.61 /

+0.3 (+0.38%)

, EA

Electronic Arts

$133.92 /

-1.93 (-1.42%)

, MGNI

Magnite

$29.21 /

-0.275 (-0.93%)

, PLTK

Playtika

$26.92 /

-1.55 (-5.44%)

, RBLX

Roblox

$80.88 /

-0.62 (-0.76%)

, ROKU

Roku

$324.19 /

+0.96 (+0.30%)

, VZIO

Vizio

$19.09 /

+0.76 (+4.15%)

, ZNGA

Zynga

$8.00 /

+0.015 (+0.19%)

Digital…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

VZIO Vizio
$19.09 /

+0.76 (+4.15%)

ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

PLTK Playtika
$26.92 /

-1.55 (-5.44%)

MGNI Magnite
$29.21 /

-0.275 (-0.93%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

09/15/21 KeyBanc
EA's delay of Battlefield 2042 slight positive for Activision, says KeyBanc
09/15/21 Benchmark
EA shares reacting negatively to Battlefield 2042 delay rumors, says Benchmark
09/15/21 Truist
Battlefield 2042 delay would be 'modest negative' for EA, says Truist
09/13/21 JPMorgan
Activision should be bought on China regulation concerns, says JPMorgan
EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

09/15/21 Raymond James
Delay of EA's Battlefield 2042 likely a 'mild negative,' says Raymond James
MGNI Magnite
$29.21 /

-0.275 (-0.93%)

09/16/21 Susquehanna
Magnite upbeat analyst reaffirms positive thesis, says Susquehanna
08/31/21 Macquarie
Macquarie starts 'SSP leader' Magnite at Outperform
08/31/21 Macquarie
Magnite initiated with an Outperform at Macquarie
08/09/21 RBC Capital
Magnite assumed with an Outperform at RBC Capital
PLTK Playtika
$26.92 /

-1.55 (-5.44%)

09/10/21 Wedbush
Wedbush says Apple injunction could boost earnings for mobile game makers
09/10/21 Baird
Apple ruling could be positive for mobile game publishers, says Baird
08/05/21 Cowen
Playtika valuation remains extremely attractive, says Cowen
06/30/21 Morgan Stanley
Morgan Stanley double downgrades overvalued AppLovin to Underweight
RBLX Roblox
$80.88 /

-0.62 (-0.76%)

09/15/21 Benchmark
Benchmark reiterates Sell rating on Roblox after 'weak' August indicators
09/15/21 Truist
Roblox key performance indicators for August 'solid,' says Truist
09/10/21 Truist
Apple will likely appeal ruling in Epic case, says Truist
08/31/21 Jefferies
China crackdown 'more serious' for Roblox than U.S. publishers, says Jefferies
ROKU Roku
$324.19 /

+0.96 (+0.30%)

09/13/21 Stephens
Recent Apple TV+ news positive for Roku, says Stephens
09/09/21 Stephens
Premium prices of Amazon TVs reduces risk for Roku, says Stephens
09/09/21 KeyBanc
New Amazon Fire TVs 'incremental positive' for Roku, says KeyBanc
09/09/21 JPMorgan
Vizio added as new best idea in SMID-cap U.S. Internet at JPMorgan
VZIO Vizio
$19.09 /

+0.76 (+4.15%)

09/14/21
Fly Intel: Top five analyst initiations
09/14/21 Stephens
Stephens starts Vizio at Overweight with $27 price target
09/13/21 Stephens
Vizio initiated with an Overweight at Stephens
ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

VZIO Vizio
$19.09 /

+0.76 (+4.15%)

ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

PLTK Playtika
$26.92 /

-1.55 (-5.44%)

MGNI Magnite
$29.21 /

-0.275 (-0.93%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

  • 25
    Mar
  • 15
    Jan
ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

VZIO Vizio
$19.09 /

+0.76 (+4.15%)

ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

PLTK Playtika
$26.92 /

-1.55 (-5.44%)

MGNI Magnite
$29.21 /

-0.275 (-0.93%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

VZIO Vizio
$19.09 /

+0.76 (+4.15%)

ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

MGNI Magnite
$29.21 /

-0.275 (-0.93%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 04:55
09/19/21
09/19
04:55
09/19/21
04:55
ABBV

AbbVie

$107.75 /

-0.33 (-0.31%)

, AYLA

Ayala Pharmaceuticals

$12.25 /

-0.01 (-0.08%)

, DCPH

Deciphera

$33.08 /

+1.45 (+4.58%)

, GMAB

Genmab

$43.10 /

+0.845 (+2.00%)

, LPTX

Leap Therapeutics

$2.65 /

+0.13 (+5.16%)

, ORIC

Oric Pharmaceuticals

$25.20 /

+0.99 (+4.09%)

, SYNH

Syneos Health

$94.34 /

+0.55 (+0.59%)

, BGNE

BeiGene

$403.60 /

+18.32 (+4.75%)

, BMY

Bristol-Myers

$61.32 /

+0.1 (+0.16%)

, BYSI

BeyondSpring

$23.00 /

+0.47 (+2.09%)

, CALA

Calithera Biosciences

$2.25 /

+0.2 (+9.76%)

, GILD

Gilead

$71.61 /

+0.34 (+0.48%)

, GH

Guardant Health

$132.01 /

+5.01 (+3.94%)

, LLY

Eli Lilly

$230.17 /

-0.78 (-0.34%)

, IPSEY

Ipsen

$23.92 /

-0.395 (-1.62%)

, EXAS

Exact Sciences

$108.29 /

+5.47 (+5.32%)

, IDYA

Ideaya Biosciences

$26.90 /

+0.9 (+3.46%)

, GSK

GlaxoSmithKline

$38.94 /

-0.16 (-0.41%)

, RHHBY

Roche

$46.07 /

-0.75 (-1.60%)

, REGN

Regeneron

$651.38 /

-2.3 (-0.35%)

, PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

, TAK

Takeda Pharmaceutical

$17.16 /

-0.045 (-0.26%)

, TMO

Thermo Fisher

$596.98 /

+36.11 (+6.44%)

, TCRR

TCR2 Therapeutics

$10.00 /

-5.715 (-36.38%)

, VERU

Veru

$8.94 /

+0.17 (+1.94%)

, VBLT

VBL Therapeutics

$2.32 /

-0.035 (-1.49%)

, VTRS

Viatris

$13.57 /

-0.13 (-0.95%)

, NVS

Novartis

$83.49 /

-0.88 (-1.04%)

ESMO 2021 Virtual…

ESMO 2021 Virtual Congress will be held on September 16-21. Webcast Link

ShowHide Related Items >><<
VTRS Viatris
$13.57 /

-0.13 (-0.95%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

IPSEY Ipsen
$23.92 /

-0.395 (-1.62%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
09/08/21 JPMorgan
AbbVie offers 'best risk/reward story in the group,' says JPMorgan
09/07/21 Morgan Stanley
Morgan Stanley cuts Vertex Pharmaceuticals to Underweight amid AbbVie overhang
AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with Buy, $29 target at Ladenburg
07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with a Buy at Ladenburg
12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

08/04/21 H.C. Wainwright
Deciphera price target lowered to $70 from $75 at H.C. Wainwright
05/05/21 Barclays
Deciphera price target lowered to $65 from $70 at Barclays
05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
GMAB Genmab
$43.10 /

+0.845 (+2.00%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
06/03/21 Baird
Leap Therapeutics transferred with Outperform at Baird
ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy after tumor data at Citi
07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

09/08/21 Baird
BeyondSpring initiated with an Outperform at Baird
08/04/21 Evercore ISI
BeyondSpring price target raised to $95 from $30 at Evercore ISI
08/04/21 William Blair
BeyondSpring may have new standard of care in lung cancer, says William Blair
08/04/21 H.C. Wainwright
Wainwright upgrades BeyondSpring with $100 target on lung cancer data
CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
GILD Gilead
$71.61 /

+0.34 (+0.48%)

07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
GH Guardant Health
$132.01 /

+5.01 (+3.94%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
IPSEY Ipsen
$23.92 /

-0.395 (-1.62%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/15/21 Canaccord
Exact Sciences progress in MRD space a positive, says Canaccord
09/01/21 Baird
UnitedHealth update to CRC screening coverage not a surprise, says Baird
IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
04/16/21 Roth Capital
Ideaya Biosciences price target raised to $31 from $23 at Roth Capital
GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
RHHBY Roche
$46.07 /

-0.75 (-1.60%)

09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
REGN Regeneron
$651.38 /

-2.3 (-0.35%)

09/15/21 Cantor Fitzgerald
Regeneron price target raised to $700 from $670 at Cantor Fitzgerald
09/15/21 H.C. Wainwright
Regeneron price target raised to $831 from $787 at H.C. Wainwright
09/15/21 Piper Sandler
Regeneron price target raised to $690 from $675 at Piper Sandler
09/09/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

08/03/21 Piper Sandler
Arcturus strength attributable to large pharma's interest in mRNA, says Piper
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

08/04/21 Credit Suisse
Thermo Fisher assumed with an Outperform at Credit Suisse
08/04/21 Argus
Thermo Fisher price target raised to $600 from $530 at Argus
07/29/21 Cowen
Thermo Fisher price target raised to $560 from $525 at Cowen
07/29/21 BTIG
Thermo Fisher price target raised to $610 from $590 at BTIG
TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

09/17/21 Wedbush
TCR2 Therapeutics downgraded to Neutral from Outperform at Wedbush
08/06/21 BMO Capital
TCR2 Therapeutics price target lowered to $44 from $53 at BMO Capital
06/24/21 Goldman Sachs
TCR2 Therapeutics initiated with a Buy at Goldman Sachs
06/11/21 BMO Capital
TCR2 Therapeutics coverage transferred at BMO Capital
VERU Veru
$8.94 /

+0.17 (+1.94%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
VTRS Viatris
$13.57 /

-0.13 (-0.95%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
NVS Novartis
$83.49 /

-0.88 (-1.04%)

09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
VTRS Viatris
$13.57 /

-0.13 (-0.95%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

  • 08
    Jul
  • 03
    Jun
  • 04
    May
  • 09
    Apr
  • 01
    Mar
  • 18
    Feb
  • 20
    Jan
  • 02
    Dec
  • 02
    Dec
  • 19
    Nov
  • 13
    Nov
  • 07
    Oct
TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

VTRS Viatris
$13.57 /

-0.13 (-0.95%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

On The Fly
Opening Day: Sports analytics company Sportradar drops in trading debut » 10:34
09/18/21
09/18
10:34
09/18/21
10:34
FORG

ForgeRock

$45.46 /

+8.86 (+24.21%)

, HZON

Horizon Acquisition Corp. II

$9.80 /

+0.04 (+0.41%)

, ACT

Enact Holdings

$20.01 /

-0.41 (-2.01%)

, ONON

On Holding

$38.95 /

+1.45 (+3.87%)

, DICE

Dice Therapeutics

$37.73 /

+1.93 (+5.39%)

, DH

Definitive Healthcare

$48.99 /

+1.87 (+3.97%)

, BROS

Dutch Bros

$43.56 /

-4.42 (-9.21%)

, TWKS

Thoughtworks

$34.06 /

+2.7 (+8.61%)

, PRCT

Procept BioRobotics

$40.03 /

+3.77 (+10.40%)

, KTTA

Pasithea Therapeutics

$3.14 /

-0.23 (-6.82%)

, SRAD

Sportradar

$27.01 /

+0.22 (+0.82%)

, RNXT

RenovoRx

$7.46 /

-0.45 (-5.69%)

, SQL

SeqLL

$3.91 /

+0.09 (+2.36%)

, DDI

DoubleDown

$17.50 /

+0.22 (+1.27%)

, QNIU

Qiniu

/

+

, CMSL

Camposol

/

+

, SPRK

Spark Education

/

+

, SCAN

Perspectum Group

/

+

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

, ARBK

Argo Blockchain

/

+

, WRBY

Warby Parker

/

+

, TOST

Toast

/

+

, HLTH

Cue Health

/

+

, ALVU

Allvue

/

+

, BIRD

Allbirds

/

+

, GTLB

GitLab

/

+

, KETR

Keter

/

+

, AMZN

Amazon.com

$3,461.96 /

-25.76 (-0.74%)

, F

Ford

$13.56 /

+0.16 (+1.19%)

, BABA

Alibaba

$160.00 /

+3.74 (+2.39%)

, EZFL

EzFill

$4.57 /

-0.62 (-11.95%)

The Switzerland-based…

ShowHide Related Items >><<
RNXT RenovoRx
$7.46 /

-0.45 (-5.69%)

ONON On Holding
$38.95 /

+1.45 (+3.87%)

FORG ForgeRock
$45.46 /

+8.86 (+24.21%)

F Ford
$13.56 /

+0.16 (+1.19%)

DDI DoubleDown
$17.50 /

+0.22 (+1.27%)

BROS Dutch Bros
$43.56 /

-4.42 (-9.21%)

BABA Alibaba
$160.00 /

+3.74 (+2.39%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

AMZN Amazon.com
$3,461.96 /

-25.76 (-0.74%)

ALVU Allvue
/

+

FORG ForgeRock
$45.46 /

+8.86 (+24.21%)

HZON Horizon Acquisition Corp. II
$9.80 /

+0.04 (+0.41%)

ACT Enact Holdings
$20.01 /

-0.41 (-2.01%)

ONON On Holding
$38.95 /

+1.45 (+3.87%)

09/17/21 Citi
Deckers Brands portfolio being 'significantly undervalued,' says Citi
DICE Dice Therapeutics
$37.73 /

+1.93 (+5.39%)

DH Definitive Healthcare
$48.99 /

+1.87 (+3.97%)

BROS Dutch Bros
$43.56 /

-4.42 (-9.21%)

TWKS Thoughtworks
$34.06 /

+2.7 (+8.61%)

PRCT Procept BioRobotics
$40.03 /

+3.77 (+10.40%)

KTTA Pasithea Therapeutics
$3.14 /

-0.23 (-6.82%)

SRAD Sportradar
$27.01 /

+0.22 (+0.82%)

RNXT RenovoRx
$7.46 /

-0.45 (-5.69%)

SQL SeqLL
$3.91 /

+0.09 (+2.36%)

DDI DoubleDown
$17.50 /

+0.22 (+1.27%)

QNIU Qiniu
/

+

CMSL Camposol
/

+

SPRK Spark Education
/

+

SCAN Perspectum Group
/

+

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

ARBK Argo Blockchain
/

+

WRBY Warby Parker
/

+

TOST Toast
/

+

HLTH Cue Health
/

+

ALVU Allvue
/

+

BIRD Allbirds
/

+

GTLB GitLab
/

+

KETR Keter
/

+

AMZN Amazon.com
$3,461.96 /

-25.76 (-0.74%)

09/14/21 Evercore ISI
Amazon price target raised to $4,700 from $4,200 at Evercore ISI
09/13/21
Fly Intel: Top five analyst initiations
09/13/21 Goldman Sachs
Amazon.com initiated with a Buy at Goldman Sachs
09/10/21 BofA
Affirm price target raised to $119 from $82 at BofA
F Ford
$13.56 /

+0.16 (+1.19%)

09/08/21 Benchmark
Worst of chip shortage could be over for Ford, says Benchmark
07/16/21 BofA
Ford price target raised to $18 from $17 at BofA
06/29/21 UBS
Ford price target raised to $16 from $13 at UBS
06/22/21 Barclays
Ford price target raised to $17 from $15 at Barclays
BABA Alibaba
$160.00 /

+3.74 (+2.39%)

09/15/21 Stifel
Alibaba price target lowered to $210 from $260 at Stifel
09/06/21 KGI Securities
Alibaba initiated with a Neutral at KGI Securities
08/20/21 Erste Group
Alibaba downgraded to Sell from Hold at Erste Group
08/05/21 Susquehanna
Alibaba price target lowered to $310 from $350 at Susquehanna
EZFL EzFill
$4.57 /

-0.62 (-11.95%)

F Ford
$13.56 /

+0.16 (+1.19%)

BABA Alibaba
$160.00 /

+3.74 (+2.39%)

AMZN Amazon.com
$3,461.96 /

-25.76 (-0.74%)

  • 24
    Sep
  • 23
    Sep
  • 15
    Sep
  • 22
    Sep
  • 16
    Sep
  • 15
    Sep
  • 15
    Sep
  • 29
    Sep
  • 15
    Sep
  • 15
    Sep
  • 15
    Sep
  • 15
    Sep
  • 16
    Sep
  • 15
    Sep
  • 14
    Sep
  • 27
    Aug
  • 26
    Aug
  • 31
    Aug
  • 16
    Jul
  • 13
    May
SRAD Sportradar
$27.01 /

+0.22 (+0.82%)

HZON Horizon Acquisition Corp. II
$9.80 /

+0.04 (+0.41%)

F Ford
$13.56 /

+0.16 (+1.19%)

BABA Alibaba
$160.00 /

+3.74 (+2.39%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

AMZN Amazon.com
$3,461.96 /

-25.76 (-0.74%)

PRCT Procept BioRobotics
$40.03 /

+3.77 (+10.40%)

ONON On Holding
$38.95 /

+1.45 (+3.87%)

HZON Horizon Acquisition Corp. II
$9.80 /

+0.04 (+0.41%)

F Ford
$13.56 /

+0.16 (+1.19%)

BABA Alibaba
$160.00 /

+3.74 (+2.39%)

AMZN Amazon.com
$3,461.96 /

-25.76 (-0.74%)

HZON Horizon Acquisition Corp. II
$9.80 /

+0.04 (+0.41%)

F Ford
$13.56 /

+0.16 (+1.19%)

BABA Alibaba
$160.00 /

+3.74 (+2.39%)

AMZN Amazon.com
$3,461.96 /

-25.76 (-0.74%)

Periodicals
Selloff on Macau casino operations reviews 'a buying opportunity,' Barron's says » 10:07
09/18/21
09/18
10:07
09/18/21
10:07
WYNN

Wynn Resorts

$83.30 /

-1.095 (-1.30%)

, LVS

Las Vegas Sands

$38.17 /

+0.66 (+1.76%)

Wynn Resorts (WYNN) and…

Wynn Resorts (WYNN) and Las Vegas Sands (LVS) shares suffered sharp losses the past couple of days amid jitters that the Macau government will impose more onerous concession, or licensing, agreements when they expire next year, Lawrence Strauss writes in this week's edition of Barron's. The rout, however, could be setting up a buying opportunity for investors who are patient and have a bankroll to withstand the unlucky streak, some analysts say. Reference Link

ShowHide Related Items >><<
WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

09/17/21
Fly Intel: Top five analyst downgrades
09/17/21 Argus
Wynn Resorts downgraded to Hold from Buy at Argus
09/17/21 Argus
Wynn Resorts downgraded to Hold from Buy at Argus
09/16/21 JPMorgan
Wynn Resorts downgraded on Macau uncertainty at JPMorgan
LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

09/17/21 Jefferies
Jefferies downgrades Las Vegas Sands on 'growth uncertainty' in Macau
09/17/21 Jefferies
Las Vegas Sands downgraded to Hold from Buy at Jefferies
09/16/21 JPMorgan
JPMorgan downgrades Las Vegas Sands on Macau uncertainty
WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

  • 09
    Feb
WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

Periodicals
COVID vaccine could lift Sanofi stock, Barron's says » 10:04
09/18/21
09/18
10:04
09/18/21
10:04
SNY

Sanofi

$48.35 /

+0.14 (+0.29%)

, PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

, AZN

AstraZeneca

$55.56 /

-1.04 (-1.84%)

, GSK

GlaxoSmithKline

$38.94 /

-0.16 (-0.41%)

Few Big Pharma companies…

Few Big Pharma companies have proved able to catch the early wave of COVID-19 vaccines and ride it to success. But Sanofi (SNY) is trying hard to show that there is a life after failure-or, as the company would prefer to put it, setback, Pierre Briancon writes in this week's edition of Barron's. While rivals Pfizer (PFE) and AstraZeneca (AZN) showed potential of cross-cooperation with smaller, nimbler partners in developing and producing vaccines against the new virus in record time, for Sanofi and partner GlaxoSmithKline (GSK), it looked more like a process of hits and misses, with a series of setbacks leading to a vaccine delay, the author notes. The jab is now in its Phase 3 trial, and Sanofi spokesman Nicolas Kressmann says the company has a good chance of producing its results "before the end of the last quarter at the earliest," which means that if everything goes according to plan, regulators the world over will then approve it for distribution within days. Reference Link

ShowHide Related Items >><<
SNY Sanofi
$48.35 /

+0.14 (+0.29%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
09/17/21 Morgan Stanley
AstraZeneca price target raised to 10,000 GBp from 9,800 GBp at Morgan Stanley
08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
SNY Sanofi
$48.35 /

+0.14 (+0.29%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

Periodicals
iPhone 13 didn't surprise, Apple stock still might, Barron's says » 09:59
09/18/21
09/18
09:59
09/18/21
09:59
AAPL

Apple

$146.00 /

-2.84 (-1.91%)

On the surface, last…

On the surface, last week's edition of Apple 's annual fall product launch event was kind of a yawner, Eric Savitz writes in this week's edition of Barron's. But dig in a little, and you can find lots to chew on, he added. The biggest takeaway is that Apple's outlook is a little brighter than skeptics on the Street would have you believe, the author contends. Reference Link

ShowHide Related Items >><<
AAPL Apple
$146.00 /

-2.84 (-1.91%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

09/17/21 Jefferies
Snap Q3 revenue estimates too low, says Jefferies
09/15/21 Oppenheimer
Apple's iPhone 13 likely to attract upgraders, says Oppenheimer
09/15/21 Deutsche Bank
Apple iPhone changes 'more incremental than transformative,' says Deutsche Bank
09/15/21 Morgan Stanley
Improved iPhone affordability raises Morgan Stanley confidence in Apple growth
AAPL Apple
$146.00 /

-2.84 (-1.91%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

Periodicals
Good news not expected when Nike reports earnings, Barron's says » 09:56
09/18/21
09/18
09:56
09/18/21
09:56
NKE

Nike

$156.41 /

-1.21 (-0.77%)

Nike has a China…

Nike has a China problem-one that could come to the fore when it releases its earnings this coming Thursday, and investors should take caution heading into the call, Ben Levisohn writes in this week's edition of Barron's. Reference Link

ShowHide Related Items >><<
NKE Nike
$156.41 /

-1.21 (-0.77%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

09/13/21
Fly Intel: Top five analyst downgrades
09/13/21 BTIG
BTIG downgrades Nike on 'severe supply chain disruptions' in Vietnam
09/13/21 BTIG
Nike downgraded to Neutral from Buy at BTIG
09/09/21 UBS
Nike more likely to rise than fall after Q1 results, says UBS
NKE Nike
$156.41 /

-1.21 (-0.77%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

Periodicals
Merck, Pfizer stand to gain amid arrival of pills to battle COVID, Barron's says » 09:30
09/18/21
09/18
09:30
09/18/21
09:30
MRK

Merck

$71.70 /

-0.25 (-0.35%)

, PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

, AVIR

Atea Pharmaceuticals

$26.23 /

-0.9 (-3.32%)

In the earliest days of…

In the earliest days of COVID-19 pandemic, investor and drug developers looked to antivirals to blunt the impact of the disease but didn't have much luck, with the only antiviral authorized by the Food and Drug Administration to date being Gilead's (GILD) Veklury, also known as remdesivir, Josh Nathan-Kazis writes in this week's edition of Barron's. But the next generation of COVID-19 antivirals are now on the way, and a pill to treat - or even prevent - COVID-19 could be available by the end of the year. Merck (MRK), Pfizer (PFE), and the biotech Atea Pharmaceuticals (AVIR) each expect late-stage data on an oral Covid-19 antiviral in the coming months. If the data are positive, the drugs provide a major opportunity for the companies-one that investors should not ignore, the author notes. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

AVIR Atea Pharmaceuticals
$26.23 /

-0.9 (-3.32%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades Merck to Equal Weight, awaits strategic action
09/07/21 Morgan Stanley
Merck downgraded to Equal Weight from Overweight at Morgan Stanley
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
AVIR Atea Pharmaceuticals
$26.23 /

-0.9 (-3.32%)

09/09/21 SVB Leerink
Atea Pharmaceuticals initiated with an Outperform at SVB Leerink
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
01/29/21 JPMorgan
Atea Pharmaceuticals price target raised to $66 from $45 at JPMorgan
11/24/20 Evercore ISI
Atea Pharmaceuticals initiated with an Outperform at Evercore ISI
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

  • 30
    Oct
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

AVIR Atea Pharmaceuticals
$26.23 /

-0.9 (-3.32%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

AVIR Atea Pharmaceuticals
$26.23 /

-0.9 (-3.32%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

Periodicals
Mining stocks offer cheap play on growth, Barron's says » 09:24
09/18/21
09/18
09:24
09/18/21
09:24
BHP

BHP Group

$55.53 /

-2.57 (-4.42%)

, RIO

Rio Tinto

$68.05 /

-2.1 (-2.99%)

, NGLOY

Anglo American

$18.06 /

-1.5899 (-8.09%)

, GLNCY

Glencore

$9.01 /

-0.17 (-1.85%)

, VALE

Vale

$16.30 /

-0.42 (-2.51%)

Big diversified mining…

Big diversified mining companies BHP Group (BHP), Rio Tinto (RIO), Anglo American (NGLOY), Glencore (GLNCY), and Vale (VALE) are in the best shape ever, Andrew Bary writes in this week's edition of Barron's. Their shares, however, trade cheaply amid worries that the good times in industrial commodities are ending. For investors willing to accept some risk, the Big Five miners offer a rich opportunity, the author argues. Reference Link

ShowHide Related Items >><<
VALE Vale
$16.30 /

-0.42 (-2.51%)

RIO Rio Tinto
$68.05 /

-2.1 (-2.99%)

GLNCY Glencore
$9.01 /

-0.17 (-1.85%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

09/14/21 Barclays
BHP Group downgraded to Equal Weight from Overweight at Barclays
08/18/21 RBC Capital
BHP Group price target lowered to 2,300 GBp from 2,400 GBp at RBC Capital
07/30/21 CLSA
Rio Tinto downgraded to Sell from Underperform at CLSA
07/08/21 Berenberg
BHP Group upgraded to Buy from Hold at Berenberg
RIO Rio Tinto
$68.05 /

-2.1 (-2.99%)

09/17/21 Morgan Stanley
Rio Tinto price target lowered to 5,410 GBp from 6,330 GBp at Morgan Stanley
09/17/21 UBS
Rio Tinto price target lowered to A$86 from A$102 at UBS
09/16/21 Deutsche Bank
Rio Tinto price target lowered to 6,000 GBp from 6,600 GBp at Deutsche Bank
09/14/21 Barclays
Rio Tinto price target lowered to 4,900 GBp from 6,000 GBp at Barclays
NGLOY Anglo American
$18.06 /

-1.5899 (-8.09%)

09/17/21 Morgan Stanley
Anglo American downgraded to Equal Weight from Overweight at Morgan Stanley
09/17/21 UBS
Anglo American downgraded to Sell from Neutral at UBS
09/16/21 Deutsche Bank
Anglo American price target lowered to 3,600 GBp at Deutsche Bank
09/14/21 Barclays
Anglo American price target lowered to 3,600 GBp from 3,700 GBp at Barclays
GLNCY Glencore
$9.01 /

-0.17 (-1.85%)

09/17/21 Morgan Stanley
Glencore upgraded to Overweight from Equal Weight at Morgan Stanley
09/16/21 RBC Capital
Glencore price target raised to 400 GBp from 360 GBp at RBC Capital
09/16/21 Deutsche Bank
Glencore price target raised to 440 GBp from 420 GBp at Deutsche Bank
09/16/21 RBC Capital
Glencore price target raised to 400 GBp from 360 GBp at RBC Capital
VALE Vale
$16.30 /

-0.42 (-2.51%)

09/17/21 UBS
Vale downgraded to Sell from Buy at UBS
07/15/21 HSBC
Vale price target raised to $27 from $25 at HSBC
07/12/21 Scotiabank
Vale price target raised to $26 from $24 at Scotiabank
07/02/21 RBC Capital
Vale price target lowered to $27 from $29 at RBC Capital
VALE Vale
$16.30 /

-0.42 (-2.51%)

VALE Vale
$16.30 /

-0.42 (-2.51%)

RIO Rio Tinto
$68.05 /

-2.1 (-2.99%)

GLNCY Glencore
$9.01 /

-0.17 (-1.85%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

GLNCY Glencore
$9.01 /

-0.17 (-1.85%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

VALE Vale
$16.30 /

-0.42 (-2.51%)

RIO Rio Tinto
$68.05 /

-2.1 (-2.99%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 04:55
09/18/21
09/18
04:55
09/18/21
04:55
ABBV

AbbVie

$107.75 /

-0.33 (-0.31%)

, AYLA

Ayala Pharmaceuticals

$12.25 /

-0.01 (-0.08%)

, DCPH

Deciphera

$33.08 /

+1.45 (+4.58%)

, GMAB

Genmab

$43.10 /

+0.845 (+2.00%)

, LPTX

Leap Therapeutics

$2.65 /

+0.13 (+5.16%)

, ORIC

Oric Pharmaceuticals

$25.20 /

+0.99 (+4.09%)

, SYNH

Syneos Health

$94.34 /

+0.55 (+0.59%)

, BGNE

BeiGene

$403.60 /

+18.32 (+4.75%)

, BMY

Bristol-Myers

$61.32 /

+0.1 (+0.16%)

, BYSI

BeyondSpring

$23.00 /

+0.47 (+2.09%)

, CALA

Calithera Biosciences

$2.25 /

+0.2 (+9.76%)

, GILD

Gilead

$71.61 /

+0.34 (+0.48%)

, GH

Guardant Health

$132.01 /

+5.01 (+3.94%)

, LLY

Eli Lilly

$230.17 /

-0.78 (-0.34%)

, IPSEY

Ipsen

$23.92 /

-0.395 (-1.62%)

, EXAS

Exact Sciences

$108.29 /

+5.47 (+5.32%)

, IDYA

Ideaya Biosciences

$26.90 /

+0.9 (+3.46%)

, GSK

GlaxoSmithKline

$38.94 /

-0.16 (-0.41%)

, RHHBY

Roche

$46.07 /

-0.75 (-1.60%)

, REGN

Regeneron

$651.38 /

-2.3 (-0.35%)

, PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

, TAK

Takeda Pharmaceutical

$17.16 /

-0.045 (-0.26%)

, TMO

Thermo Fisher

$596.98 /

+36.11 (+6.44%)

, TCRR

TCR2 Therapeutics

$10.00 /

-5.715 (-36.38%)

, VERU

Veru

$8.94 /

+0.17 (+1.94%)

, VBLT

VBL Therapeutics

$2.32 /

-0.035 (-1.49%)

, VTRS

Viatris

$13.57 /

-0.13 (-0.95%)

, NVS

Novartis

$83.49 /

-0.88 (-1.04%)

ESMO 2021 Virtual…

ESMO 2021 Virtual Congress will be held on September 16-21. Webcast Link

ShowHide Related Items >><<
VTRS Viatris
$13.57 /

-0.13 (-0.95%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

IPSEY Ipsen
$23.92 /

-0.395 (-1.62%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
09/08/21 JPMorgan
AbbVie offers 'best risk/reward story in the group,' says JPMorgan
09/07/21 Morgan Stanley
Morgan Stanley cuts Vertex Pharmaceuticals to Underweight amid AbbVie overhang
AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with Buy, $29 target at Ladenburg
07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with a Buy at Ladenburg
12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

08/04/21 H.C. Wainwright
Deciphera price target lowered to $70 from $75 at H.C. Wainwright
05/05/21 Barclays
Deciphera price target lowered to $65 from $70 at Barclays
05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
GMAB Genmab
$43.10 /

+0.845 (+2.00%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
06/03/21 Baird
Leap Therapeutics transferred with Outperform at Baird
ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy after tumor data at Citi
07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

09/08/21 Baird
BeyondSpring initiated with an Outperform at Baird
08/04/21 Evercore ISI
BeyondSpring price target raised to $95 from $30 at Evercore ISI
08/04/21 William Blair
BeyondSpring may have new standard of care in lung cancer, says William Blair
08/04/21 H.C. Wainwright
Wainwright upgrades BeyondSpring with $100 target on lung cancer data
CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
GILD Gilead
$71.61 /

+0.34 (+0.48%)

07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
GH Guardant Health
$132.01 /

+5.01 (+3.94%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
IPSEY Ipsen
$23.92 /

-0.395 (-1.62%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/15/21 Canaccord
Exact Sciences progress in MRD space a positive, says Canaccord
09/01/21 Baird
UnitedHealth update to CRC screening coverage not a surprise, says Baird
IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
04/16/21 Roth Capital
Ideaya Biosciences price target raised to $31 from $23 at Roth Capital
GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
RHHBY Roche
$46.07 /

-0.75 (-1.60%)

09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
REGN Regeneron
$651.38 /

-2.3 (-0.35%)

09/15/21 Cantor Fitzgerald
Regeneron price target raised to $700 from $670 at Cantor Fitzgerald
09/15/21 H.C. Wainwright
Regeneron price target raised to $831 from $787 at H.C. Wainwright
09/15/21 Piper Sandler
Regeneron price target raised to $690 from $675 at Piper Sandler
09/09/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

08/03/21 Piper Sandler
Arcturus strength attributable to large pharma's interest in mRNA, says Piper
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

08/04/21 Credit Suisse
Thermo Fisher assumed with an Outperform at Credit Suisse
08/04/21 Argus
Thermo Fisher price target raised to $600 from $530 at Argus
07/29/21 Cowen
Thermo Fisher price target raised to $560 from $525 at Cowen
07/29/21 BTIG
Thermo Fisher price target raised to $610 from $590 at BTIG
TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

09/17/21 Wedbush
TCR2 Therapeutics downgraded to Neutral from Outperform at Wedbush
08/06/21 BMO Capital
TCR2 Therapeutics price target lowered to $44 from $53 at BMO Capital
06/24/21 Goldman Sachs
TCR2 Therapeutics initiated with a Buy at Goldman Sachs
06/11/21 BMO Capital
TCR2 Therapeutics coverage transferred at BMO Capital
VERU Veru
$8.94 /

+0.17 (+1.94%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
VTRS Viatris
$13.57 /

-0.13 (-0.95%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
NVS Novartis
$83.49 /

-0.88 (-1.04%)

09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
VTRS Viatris
$13.57 /

-0.13 (-0.95%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

  • 08
    Jul
  • 03
    Jun
  • 04
    May
  • 09
    Apr
  • 01
    Mar
  • 18
    Feb
  • 20
    Jan
  • 02
    Dec
  • 02
    Dec
  • 19
    Nov
  • 13
    Nov
  • 07
    Oct
TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

VTRS Viatris
$13.57 /

-0.13 (-0.95%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

Conference/Events
Truist to hold a virtual bus tour » 04:55
09/18/21
09/18
04:55
09/18/21
04:55
ATVI

Activision Blizzard

$79.61 /

+0.3 (+0.38%)

, EA

Electronic Arts

$133.92 /

-1.93 (-1.42%)

, MGNI

Magnite

$29.21 /

-0.275 (-0.93%)

, PLTK

Playtika

$26.92 /

-1.55 (-5.44%)

, RBLX

Roblox

$80.88 /

-0.62 (-0.76%)

, ROKU

Roku

$324.19 /

+0.96 (+0.30%)

, VZIO

Vizio

$19.09 /

+0.76 (+4.15%)

, ZNGA

Zynga

$8.00 /

+0.015 (+0.19%)

Digital…

Digital Entertainment/Digital Marketing Virtual Bus Tour will be held on September 13-21.

ShowHide Related Items >><<
ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

VZIO Vizio
$19.09 /

+0.76 (+4.15%)

ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

PLTK Playtika
$26.92 /

-1.55 (-5.44%)

MGNI Magnite
$29.21 /

-0.275 (-0.93%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

09/15/21 KeyBanc
EA's delay of Battlefield 2042 slight positive for Activision, says KeyBanc
09/15/21 Benchmark
EA shares reacting negatively to Battlefield 2042 delay rumors, says Benchmark
09/15/21 Truist
Battlefield 2042 delay would be 'modest negative' for EA, says Truist
09/13/21 JPMorgan
Activision should be bought on China regulation concerns, says JPMorgan
EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

09/15/21 Raymond James
Delay of EA's Battlefield 2042 likely a 'mild negative,' says Raymond James
MGNI Magnite
$29.21 /

-0.275 (-0.93%)

09/16/21 Susquehanna
Magnite upbeat analyst reaffirms positive thesis, says Susquehanna
08/31/21 Macquarie
Macquarie starts 'SSP leader' Magnite at Outperform
08/31/21 Macquarie
Magnite initiated with an Outperform at Macquarie
08/09/21 RBC Capital
Magnite assumed with an Outperform at RBC Capital
PLTK Playtika
$26.92 /

-1.55 (-5.44%)

09/10/21 Wedbush
Wedbush says Apple injunction could boost earnings for mobile game makers
09/10/21 Baird
Apple ruling could be positive for mobile game publishers, says Baird
08/05/21 Cowen
Playtika valuation remains extremely attractive, says Cowen
06/30/21 Morgan Stanley
Morgan Stanley double downgrades overvalued AppLovin to Underweight
RBLX Roblox
$80.88 /

-0.62 (-0.76%)

09/15/21 Benchmark
Benchmark reiterates Sell rating on Roblox after 'weak' August indicators
09/15/21 Truist
Roblox key performance indicators for August 'solid,' says Truist
09/10/21 Truist
Apple will likely appeal ruling in Epic case, says Truist
08/31/21 Jefferies
China crackdown 'more serious' for Roblox than U.S. publishers, says Jefferies
ROKU Roku
$324.19 /

+0.96 (+0.30%)

09/13/21 Stephens
Recent Apple TV+ news positive for Roku, says Stephens
09/09/21 Stephens
Premium prices of Amazon TVs reduces risk for Roku, says Stephens
09/09/21 KeyBanc
New Amazon Fire TVs 'incremental positive' for Roku, says KeyBanc
09/09/21 JPMorgan
Vizio added as new best idea in SMID-cap U.S. Internet at JPMorgan
VZIO Vizio
$19.09 /

+0.76 (+4.15%)

09/14/21
Fly Intel: Top five analyst initiations
09/14/21 Stephens
Stephens starts Vizio at Overweight with $27 price target
09/13/21 Stephens
Vizio initiated with an Overweight at Stephens
ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

VZIO Vizio
$19.09 /

+0.76 (+4.15%)

ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

PLTK Playtika
$26.92 /

-1.55 (-5.44%)

MGNI Magnite
$29.21 /

-0.275 (-0.93%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

  • 25
    Mar
  • 15
    Jan
ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

VZIO Vizio
$19.09 /

+0.76 (+4.15%)

ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

PLTK Playtika
$26.92 /

-1.55 (-5.44%)

MGNI Magnite
$29.21 /

-0.275 (-0.93%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

ZNGA Zynga
$8.00 /

+0.015 (+0.19%)

VZIO Vizio
$19.09 /

+0.76 (+4.15%)

ROKU Roku
$324.19 /

+0.96 (+0.30%)

RBLX Roblox
$80.88 /

-0.62 (-0.76%)

MGNI Magnite
$29.21 /

-0.275 (-0.93%)

EA Electronic Arts
$133.92 /

-1.93 (-1.42%)

ATVI Activision Blizzard
$79.61 /

+0.3 (+0.38%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.